Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

British Journal of Cancer, Published online: 15 July 2019; doi:10.1038/s41416-019-0517-3Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Source: British Journal of Cancer - July 14, 2019 Category: Cancer & Oncology Authors: Zachary W. Veitch David W. Cescon Trisha Denny Lisa-Maria Yonemoto Graham Fletcher Richard Brokx Peter Sampson Sze-Wan Li Trevor J. Pugh Jeffrey Bruce Mark R. Bray Dennis J. Slamon Tak W. Mak Zev A. Wainberg Philippe L. Bedard Source Type: research